# Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)

> **NCT00127777** · PHASE4 · UNKNOWN · sponsor: **University Hospital, Saarland** · enrollment: 700 (—)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Amantadine sulphate (in addition to standard treatment)

## Key facts

- **NCT ID:** NCT00127777
- **Lead sponsor:** University Hospital, Saarland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 700 (—)
- **Last updated:** 2005-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127777, "Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00127777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*